Q3 2025 Trading Update
Shield Therapeutics PLC reported its Q3 2025 trading update, highlighting its strongest quarterly performance to date. ACCRUFeR® prescriptions grew by approximately 15% compared to Q2 2025, reaching roughly 54,000. This prescription volume drove net revenues to $13.1 million, with an average net selling price of $237. In comparison, Q3 2024 saw $7.2 million in net revenues from approximately 44,000 prescriptions at an average net selling price of $167. The company's cash and cash equivalents stood at $8.6 million as of September 30, 2025. Shield Therapeutics remains on track to achieve cash flow positivity by the end of 2025.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
$13.1m net revenues and an average net selling price of $237
Guidance remains to turn cash flow positive by the end of 2025
London, UK, 23 October 2025: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, provides an unaudited Q3 2025 trading update.
In the third quarter of 2025, Shield reported unaudited ACCRUFeR® net revenues of $13.1m, c. 54,000 total prescriptions and an average net selling price of $237, this compared to $7.2m, c. 44,000 and $167 respectively in Q3 2024. Given the strong momentum entering Q4 2025 with September generating >40% of Q3 2025 revenues, the Company remains on track to achieve its prior guidance of turning cash flow positive by the end of 2025.
Q3 2025 Key Business Metrics:
- ACCRUFeR® net revenue of $13.1m (Q2 2025: $12.8m and Q3 2024: $7.2m).
- ACCRUFeR® average net selling price of $237 (Q2 2025: $231 and Q3 2024: $167).
- ACCRUFeR® prescriptions of c. 54,000, with c. 22% consignment-based prescriptions that were dispensed at a significantly subsidised price to patients and were not yet reimbursed by payors.
- Cash and cash equivalents of $8.6m as of 30 September 2025 ($10.8m as of 30 June 2025) including receipt of net proceeds from placing announced in the period.
- The company remains on track to turn cash flow positive by the end of 2025
Anders Lundstrom, Chief Executive Officer, commented: "I am very pleased to see ACCRUFeR®'s strong performance continue into Q3 2025. The combined efforts of the Shield and Viatris Sales team along with our strategic marketing initiatives have driven continued strong performance in Q3, marking our strongest quarter on record with a new high in prescription volumes, net selling price, and revenues. This was further underscored in September, which delivered the highest net revenue month to date representing >40% of the Q3 ACCRUFeR® revenues. This performance has reinforced our alignment with full-year performance targets enabling us to stay on track to turning cash flow positive by the end of 2025"
Investor Presentation via Investor Meet Company
CEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the Q3 2025 Trading Update via the Investor Meet Company platform at 3:00 pm (BST) on 23 October 2025.
The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 2.00 pm (BST) or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via:
Investors who already follow Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today for ID/IDA (data source - IQVIA Xponent PlanTrak).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.